Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 27, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
December 03, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
November 18, 2021 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

Investigational New Drug Application for ATI-2138 Allowed WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused...
November 03, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
November 02, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moderate to Severe Rheumatoid...
August 27, 2021 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
August 26, 2021 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
August 05, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in...
July 08, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
June 09, 2021 19:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Announces Pricing of Public Offering of Common Stock

WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...